<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895439</url>
  </required_header>
  <id_info>
    <org_study_id>MSUJCTC</org_study_id>
    <nct_id>NCT01895439</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis</brief_title>
  <official_title>Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <authority>Jordan: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Expanding and priming Bone Marrow (BM)- Mesenchymal Stem Cells (MSCs) to a clinical
           scale according to Good Laboratory Practice using xenogenic free media instead of the
           previously used FCS.

        2. Assessing the safety of injecting autologous BM-MSCs to Multiple Sclerosis (MS)patients
           who fail to respond to conventional treatment.

        3. Assessing the therapeutic benefits on the participants in the trial as per established
           methods.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessing the safety of autologous Mesenchymal Stem Cells injection by recording the number of patients with any relevant side effects observed</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For every patient tests would be performed at baseline and repeated at 3, 6, and 18 months post-injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Primed Mesenchymal Stem Cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesenchymal Stem Cells primed prior to injection to have a more effective anti inflammatory effect for Multiple Sclerosis Patients who do not respond to conventional treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unprimed  autologous MSCs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesenchymal Stem Cells injected to Multiple Sclerosis enrolled patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Mesenchymal Stem Cells</intervention_name>
    <arm_group_label>Primed Mesenchymal Stem Cells</arm_group_label>
    <arm_group_label>unprimed  autologous MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of definite MS according to the revised McDonald Criteria.

          -  Expanded Disability Status Scale (EDSS) â‰¤ 6

          -  Failure of standard medical therapy

          -  Disease duration of at least three years prior to enrollment.

        Exclusion Criteria:

          -  Pregnant and lactating women

          -  Previous treatment with immunosuppressive agents in the last 12 months prior to
             enrollment

          -  Recent MS relapse in the month prior to enrollment

          -  Treatment with oral or parenteral steroids for any cause in the month prior to
             enrollment

          -  Significant systemic medical disorders including cardiac, renal, hepatic,
             hematologic, immunologic or endocrine disorders

          -  Previous treatment with interferons or glatiramer acetate in the 3 months prior to
             enrollment

          -  Any contra-indication for magnetic resonance imaging (MRI) or gadolinium    contrast.

          -  Positive serology for HIV, Hepatitis B or Hepatitis C

          -  Any history of malignancy or exposure to radiation at any time prior to enrollment

          -  Any contra-indication to lumbar puncture

          -  Severe cognitive impairment that would interfere with the patient's ability to
             understand and sign the informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdallah Awidi, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Cell Therapy Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Said Dahbour, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jordan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatima Abbas Jamali, MSc.</last_name>
    <phone>009625355000</phone>
    <phone_ext>23960</phone_ext>
    <email>ftmjamali@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Majed Hattab, MSc.</last_name>
    <phone>009625355000</phone>
    <phone_ext>23960</phone_ext>
    <email>d.hattab@ju.edu.jo</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cell Therapy Center, Jordan University Hospital</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima Jamali, MSc.</last_name>
      <phone>009625355000</phone>
      <phone_ext>23960</phone_ext>
      <email>ftmjamali@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dana Hattab, MSc.</last_name>
      <phone>009625355000</phone>
      <phone_ext>23960</phone_ext>
      <email>d.hattab@ju.edu.jo</email>
    </contact_backup>
    <investigator>
      <last_name>Osama H Ababneh, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yacoub Bahou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muawyah Bdour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nusayba Ryalat, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imad Tarawneh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 3, 2013</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Fatima Jamali</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Bone marrow derived Mesenchymal Stem Cells</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Oligodendrocytes</keyword>
  <keyword>Neuroimmunology</keyword>
  <keyword>Autoimmune disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
